ALX Oncology Holdings has the Financial Strength Rank of 7.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
ALX Oncology Holdings did not have earnings to cover the interest expense.
As of today, ALX Oncology Holdings's Altman Z-Score is 0.00.
Competitive Comparison
For the Biotechnology subindustry, ALX Oncology Holdings's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ALX Oncology Holdings Financial Strength Distribution
For the Biotechnology industry and Healthcare sector, ALX Oncology Holdings's Financial Strength distribution charts can be found below:
* The bar in red indicates where ALX Oncology Holdings's Financial Strength falls into.
ALX Oncology Holdings Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
ALX Oncology Holdings's Interest Expense for the
months ended in Dec. 2023 was $-0.42 Mil. Its Operating Income for the
months ended in Dec. 2023 was $-48.02 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $15.62 Mil.
ALX Oncology Holdings's Interest Coverage for the quarter that ended in Dec. 2023 is
| ALX Oncology Holdings did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
ALX Oncology Holdings's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
ALX Oncology Holdings has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALX Oncology Holdings (ALX Oncology Holdings) Business Description
Traded in Other Exchanges
N/A
Address
323 Allerton Avenue, South San Francisco, CA, USA, 94080
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Executives
| Shelly Pinto |
officer: VP, Finance and CAO |
866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010 |
| Peter S Garcia |
officer: Chief Financial Officer |
ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010 |
| Sophia Randolph |
officer: Chief Medical Officer |
C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010 |
| Jaume Pons |
director, officer: President and CEO |
C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010 |
| J. Scott Garland |
director |
210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
| Itziar Canamasas |
director |
C/O ALX ONCOLOGY HOLDINGS INC, 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080 |
| Jason Lettmann |
director, 10 percent owner |
C/O RA PHARMACEUTICALS, INC., 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140 |
| Lsv Associates, Llc |
10 percent owner |
2884 SAND HILL ROAD, SUITE 121, MENLO PARK CA 94025 |
| G. Walmsley Graham |
director |
ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
| Goodman Corey S |
director, 10 percent owner, other: Executive Chairman |
1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
| Rekha Hemrajani |
director |
3928 POINT EDEN WAY, HAYWARD CA 94545 |
| Venbio Global Strategic Fund, L.p. |
10 percent owner, other: See Remarks |
1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
| Vivo Opportunity Fund, L.p. |
10 percent owner |
192 LYTTON AVENUE, PALO ALTO CA 94301 |
| Vivo Opportunity, Llc |
10 percent owner |
192 LYTTON AVENUE, PALO ALTO CA 94301 |
| Steffen Pietzke |
officer: VP Fin & Chief Acct Officer |
C/O ENOVIX CORPORATION, 3501 W. WARREN AVENUE, FREMONT CA 94538 |
ALX Oncology Holdings (ALX Oncology Holdings) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALXO has been successfully added to your